Advancement in the area of multiple myeloma and development of connected laboratory background

Česká verzia

Authors: R. Hájek ^1–3; M. Almaši ^1,3 ; L. Říhová ^1,3; J. Smejkalová ^1,3; L. Pour ²; L. Zahradová ^1,2; Z. Adam ²
Authors place of work: Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc. ¹; Interní hematoonkologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ²; Babákova myelomová skupina při Ústavu patologické fyziologie LF MU Brno, přednostka prof. MUDr. Anna Vašků, CSc. ³
Published in the journal: Vnitř Lék 2012; 58(7 a 8): 135-140
Category: 60th Birthday prof. MUDr. Miroslav Penka, CSc.

Summary

Development in research, diagnostics and treatment of multiple myeloma has been unprecedented in the past 10 years. One of the basic conditions of research is entry processing and sorting of biological material as well as creation of a biobank with archiving of a critical amount of samples for research. This work described the development and functioning of a research laboratory of experimental hematology that needs to answer high demands of quickly developing research of multiple myeloma and other monoclonal gammopathies for entry processing and sorting of material and its archiving for research as well as diagnostics needs.

Key words:
multiple myeloma – monoclonal gammopathy – biobank – flow cytometry

Zdroje

1. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Barlogie B, Shaughnessy JD Jr, Anaissie E et al. Modeling for cure with total therapy (TT) trials for newly diagnosed multiple myeloma (MM): let the math speak. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 744.

3. Hoering A, Crowley J, Shaughnessy JD Jr et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009; 114: 1299–1305.

4. Van Rhee F, Szymonifka J, Anaissie E et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116: 1220–1227.

5. San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica 2011; 96: 1246–1248.

6. Kovářová L, Varmužová T, Zarbochová P et al. Průtoková cytometrie u monoklonálních gamapatií. Klin Onkol 2011; 24 (Suppl): 24–29.

7. Ševčíková S, Němec P, Pour L et al. Genomika ve výzkumu mnohočetného myelomu. Klin Onkol 2011; 24 (Suppl): 34–38.

8. Yuille M, van Ommen GJ, Bréchot C et al. Biobanking for Europe. Brief Bioinform 2008; 9: 14–24.

9. Lochmüller H, Schneiderat P. Biobanking in rare disorders. Adv Exp Med Biol 2010; 686: 105–113.

10. Kovarova L, Buresova I, Buchler T et al. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma 2009; 56: 526–532.

11. Fišerová A, Hájek R, Doubek M et al. Imunomagnetická separace myelomových buněk. Klin Onkol 2001; 14: 46–50.

12. Čumová J, Burešová I, Kovářová L et al. Selekce plazmatických buněk. Klin Onkol 2008; 21 (Suppl 1): 190–194.

13. Cumova J, Kovarova L, Potacova A et al. Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting. Int J Hematol 2010; 92: 314–319.

14. Burešová I, Čumová J, Kovářová L et al. Srovnání selekce plazmatických buněk metodami MACS a FACS. Klin Onkol 2008; 21 (Suppl 1): 195–197.

15. Buresova I, Cumova J, Kovarova L et al. Bone marrow plasma cell separation – validation of separation algorithm. Clin Chem Lab Med 2012; 50: DOI 10.1515/cclm-2011-0837.

16. Burešová I, Kyjovská D, Kovářová L. Algoritmus separace plazmatických buněk ze vzorků kostní dřeně. Klin Onkol 2011; 24: 35–40.

17. Almasi M, Sevcikova S, Svachova H et al. Polymorphisms contribution to the determination of significant risk of specific toxicities in multiple myeloma. Klin Onkol 2011; 24 (Suppl): S39–S42.

18. Almasi M, Sevcikova S, Slaby O et al. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin Lymphoma Myeloma Leuk 2011; 11: 414–420.

19. Potacova A, Stossova J, Buresova I et al. Sample processing and methodological pitfalls in multiple myeloma research. Klin Oncol 2011; 24 (Suppl): 18–24.

20. Morgan G, Johnsen HE, Goldschmidt H et al. MyelomA Genetics International Consortium. Leuk Lymphoma 2012; 53: 796–800.

21. Brown M, Wittwer C. Flow cytometry: principles and clinical applications in hematology. Clin Chem 2000; 46: 1221–1229.

22. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3941–3967.

23. Buchler T, Kovarova L, Musilova R et al. Generation of dendritic cells using cell culture bag – description of a method and review of literature. Hematology 2004; 9: 199–205.

24. Kovarova L, Buchler T, Pour L et al. Dendritic cell counts and their subsets during treatment of multiple myeloma. Neoplasma 2007; 54: 297–303.

25. Ocadlikova D, Zahradova L, Kovarova L et al. The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells. Klin Onkol 2009; 22: 67–72.

26. Zahradova L, Mollova K, Ocadlikova D et al. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results. Neoplasma 2012; 59: 440–449.

27. Ocadlikova D, Kryukov F, Mollova K et al. Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT-drived nonapeptides or myeloma cell apoptotic bodies. Neoplasma 2010; 57: 455–464.

28. Zahradová L, Očadlíková D, Kovářová L et al. Hodnocení protinádorového efektu antigen-specifických T-lymfocytů s využitím neradioaktivního testu cytotoxicity. Transfuze Hematol Dnes 2006; 12: 244–248.

29. Kovářová L, Hájek R. Flowcytometrická analýza plazmatických buněk u mnohočetného myelomu. Klin Onkol 2008; 21 (Suppl): 249–252.

30. Paiva B, Almeida J, Pérez-Andrés M et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010; 78: 239–252.

31. Kovářová L, Hájek R. Prognostický význam imunofenotypizace u nemocných s monoklonální gamapatií nejasného významu a mnohocetným myelomem. Klin Biochem Metab 2011; 19: 96–100.

32. Rawstron AC, Orfao A, Beksac M et al. European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431–438.